The New England Journal Of Medicine 2026 PMID: 42253238, DOI: 10.1056/nejmoa2600751.Peer-Reviewed Original ResearchAltmetricConceptsGlucagon-like peptide-1Dose escalation periodPlacebo groupEarly discontinuationBody weightTreatment of adultsDouble-blind trialPhase 2 trialBaseline to weekObesity-related complicationsManagement of obesityObesity medicationsBody-mass indexMean BMIPlaceboEfficacy analysisNo deathsAdverse eventsCardiometabolic benefitsMean body weightGastrointestinal symptomsLifestyle modificationParticipantsEnd pointsAdults Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Rosenstock J, Lingvay I, Ryan D, Jastreboff A , Kushner R, Acosta A, Blevins T, Choi M, Holmes F, Smith T, Connery L, Li Y, Liu M, Barth A, Butcher J, Civitarese A, Yue H, Coll B
Hydrolyzed Collagen
Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis
IGF-1 LR3 is a complex analog where analytical results must be interpreted with method-specific context
